DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Clinical trial NCT03255083 · TERMINATED
Trial details
- NCT number
- NCT03255083
- Sponsor
- Daiichi Sankyo
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-10
- Primary completion
- 2020-09-04
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.